Yarrow Bioscience Inc (NASDAQ: YARW) is a Healthcare company (Biotechnology) with a market capitalization of $134M. The Maz Rating grades it against the other companies in its sector.
Yarrow Bioscience Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $14.21, Yarrow Bioscience Inc trades at 427.6x sales and 1.2x book value, with an EV/EBITDA of 6.5. Over the last twelve months it generated about $313662 of revenue and a net loss of $145M. It runs a gross margin of 96.2%, an operating margin of -7309.9% and a net margin of -6758.1%. It shows return on equity of -24.7%, return on invested capital of -8.6% and a free cash flow yield of -75.4%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 42.08. Over the past 52 weeks the share price ranged from $12.38 to $46.95, with a beta of 2.13.
Yarrow Bioscience Inc pays a dividend yielding 141.75%.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Yarrow Bioscience Inc (YARW) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 499.4% / 30% · Interest income / Revenue 92500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 499.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 92500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 499.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 92500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 92500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.1% / 33.33% · (Cash+Recv) / Total Assets 98.1% / 33.33% · Interest income / Revenue 92500000.0% / 5% | Fail |
No. As of September 2026, Yarrow Bioscience Inc (YARW) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Yarrow Bioscience Inc is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 92500000.0% of each dividend: Yarrow Bioscience Inc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.